首页 > 最新文献

Annual Reports in Medicinal Chemistry最新文献

英文 中文
The challenges and opportunities of developing small molecule inhibitors of MraY. 开发 MraY 小分子抑制剂的挑战与机遇。
4区 化学 Q3 Chemistry Pub Date : 2023-01-01 Epub Date: 2023-10-11 DOI: 10.1016/bs.armc.2023.09.005
Destinee Manning, Tzu-Yu Huang, Tomayo Berida, Sudeshna Roy
{"title":"The challenges and opportunities of developing small molecule inhibitors of MraY.","authors":"Destinee Manning, Tzu-Yu Huang, Tomayo Berida, Sudeshna Roy","doi":"10.1016/bs.armc.2023.09.005","DOIUrl":"10.1016/bs.armc.2023.09.005","url":null,"abstract":"","PeriodicalId":8033,"journal":{"name":"Annual Reports in Medicinal Chemistry","volume":"60 ","pages":"1-27"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11250723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141625805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The limited role of most circRNAs as sponges for microRNAs. 大多数 circRNA 作为 microRNA 的海绵作用有限。
IF 8 4区 化学 Q3 Chemistry Pub Date : 2022-05-19 DOI: 10.1007/s00018-022-04370-7
Ye-Zhao Wang
{"title":"The limited role of most circRNAs as sponges for microRNAs.","authors":"Ye-Zhao Wang","doi":"10.1007/s00018-022-04370-7","DOIUrl":"10.1007/s00018-022-04370-7","url":null,"abstract":"","PeriodicalId":8033,"journal":{"name":"Annual Reports in Medicinal Chemistry","volume":"28 1","pages":"299"},"PeriodicalIF":8.0,"publicationDate":"2022-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11072715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77728470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preface 前言
4区 化学 Q3 Chemistry Pub Date : 2021-11-17 DOI: 10.1016/S0065-7743(21)00029-4
K. Seley‐Radtke
{"title":"Preface","authors":"K. Seley‐Radtke","doi":"10.1016/S0065-7743(21)00029-4","DOIUrl":"https://doi.org/10.1016/S0065-7743(21)00029-4","url":null,"abstract":"","PeriodicalId":8033,"journal":{"name":"Annual Reports in Medicinal Chemistry","volume":"57 1","pages":"xi - xv"},"PeriodicalIF":0.0,"publicationDate":"2021-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44282395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Broad spectrum antiviral nucleosides-Our best hope for the future. 广谱抗病毒核苷——我们对未来的最大希望。
4区 化学 Q3 Chemistry Pub Date : 2021-01-01 DOI: 10.1016/bs.armc.2021.09.001
Katherine L Seley-Radtke, Joy E Thames, Charles D Waters

The current focus for many researchers has turned to the development of therapeutics that have the potential for serving as broad-spectrum inhibitors that can target numerous viruses, both within a particular family, as well as to span across multiple viral families. This will allow us to build an arsenal of therapeutics that could be used for the next outbreak. In that regard, nucleosides have served as the cornerstone for antiviral therapy for many decades. As detailed herein, many nucleosides have been shown to inhibit multiple viruses due to the conserved nature of many viral enzyme binding sites. Thus, it is somewhat surprising that up until very recently, many researchers focused more on "one bug one drug," rather than trying to target multiple viruses given those similarities. This attitude is now changing due to the realization that we need to be proactive rather than reactive when it comes to combating emerging and reemerging infectious diseases. A brief summary of prominent nucleoside analogues that previously exhibited broad-spectrum activity and are now under renewed interest, as well as new analogues, that are currently under investigation against SARS-CoV-2 and other viruses is discussed herein.

目前,许多研究人员的重点已转向开发具有广谱抑制剂潜力的治疗方法,这种抑制剂可以针对特定家族中的许多病毒,也可以跨越多个病毒家族。这将使我们能够建立一个可用于下一次疫情爆发的治疗药物库。在这方面,核苷几十年来一直是抗病毒治疗的基石。正如本文所详述的,由于许多病毒酶结合位点的保守性,许多核苷已被证明可以抑制多种病毒。因此,令人惊讶的是,直到最近,许多研究人员更多地关注“一种病毒一种药物”,而不是试图针对多种病毒,因为这些相似之处。这种态度现在正在改变,因为我们认识到,在防治新出现和再出现的传染病方面,我们需要积极主动,而不是被动被动。本文简要总结了以前表现出广谱活性的突出核苷类似物,现在重新引起了人们的兴趣,以及目前正在研究的针对SARS-CoV-2和其他病毒的新类似物。
{"title":"Broad spectrum antiviral nucleosides-Our best hope for the future.","authors":"Katherine L Seley-Radtke,&nbsp;Joy E Thames,&nbsp;Charles D Waters","doi":"10.1016/bs.armc.2021.09.001","DOIUrl":"https://doi.org/10.1016/bs.armc.2021.09.001","url":null,"abstract":"<p><p>The current focus for many researchers has turned to the development of therapeutics that have the potential for serving as broad-spectrum inhibitors that can target numerous viruses, both within a particular family, as well as to span across multiple viral families. This will allow us to build an arsenal of therapeutics that could be used for the next outbreak. In that regard, nucleosides have served as the cornerstone for antiviral therapy for many decades. As detailed herein, many nucleosides have been shown to inhibit multiple viruses due to the conserved nature of many viral enzyme binding sites. Thus, it is somewhat surprising that up until very recently, many researchers focused more on \"one bug one drug,\" rather than trying to target multiple viruses given those similarities. This attitude is now changing due to the realization that we need to be proactive rather than reactive when it comes to combating emerging and reemerging infectious diseases. A brief summary of prominent nucleoside analogues that previously exhibited broad-spectrum activity and are now under renewed interest, as well as new analogues, that are currently under investigation against SARS-CoV-2 and other viruses is discussed herein.</p>","PeriodicalId":8033,"journal":{"name":"Annual Reports in Medicinal Chemistry","volume":"57 ","pages":"109-132"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10726369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
The search for antivirals to treat alphavirus infections 寻找治疗甲病毒感染的抗病毒药物
4区 化学 Q3 Chemistry Pub Date : 2021-01-01 DOI: 10.1016/bs.armc.2021.09.002
Marcella Bassetto, A. Brancale
{"title":"The search for antivirals to treat alphavirus infections","authors":"Marcella Bassetto, A. Brancale","doi":"10.1016/bs.armc.2021.09.002","DOIUrl":"https://doi.org/10.1016/bs.armc.2021.09.002","url":null,"abstract":"","PeriodicalId":8033,"journal":{"name":"Annual Reports in Medicinal Chemistry","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54061853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Inhibitors of Ebolavirus targeting innate immune evasion 针对先天免疫逃避的埃博拉病毒抑制剂
4区 化学 Q3 Chemistry Pub Date : 2021-01-01 DOI: 10.1016/bs.armc.2021.09.003
A. Paulis, A. Corona, E. Tramontano
{"title":"Inhibitors of Ebolavirus targeting innate immune evasion","authors":"A. Paulis, A. Corona, E. Tramontano","doi":"10.1016/bs.armc.2021.09.003","DOIUrl":"https://doi.org/10.1016/bs.armc.2021.09.003","url":null,"abstract":"","PeriodicalId":8033,"journal":{"name":"Annual Reports in Medicinal Chemistry","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54061920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Anno 2021: Which antivirals for the coming decade? 《纪元2021》:未来十年有哪些抗病毒药物?
4区 化学 Q3 Chemistry Pub Date : 2021-01-01 DOI: 10.1016/bs.armc.2021.09.004
Elisabetta Groaz, Erik De Clercq, Piet Herdewijn

Despite considerable progress in the development of antiviral drugs, among which anti-immunodeficiency virus (HIV) and anti-hepatitis C virus (HCV) medications can be considered real success stories, many viral infections remain without an effective treatment. This not only applies to infectious outbreaks caused by zoonotic viruses that have recently spilled over into humans such as severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), but also ancient viral diseases that have been brought under control by vaccination such as variola (smallpox), poliomyelitis, measles, and rabies. A largely unsolved problem are endemic respiratory infections due to influenza, respiratory syncytial virus (RSV), and rhinoviruses, whose associated morbidity will likely worsen with increasing air pollution. Furthermore, climate changes will expose industrialized countries to a dangerous resurgence of viral hemorrhagic fevers, which might also become global infections. Herein, we summarize the recent progress that has been made in the search for new antivirals against these different threats that the world population will need to confront with increasing frequency in the next decade.

尽管抗病毒药物的发展取得了相当大的进展,其中抗免疫缺陷病毒(HIV)和抗丙型肝炎病毒(HCV)药物可以被认为是真正的成功案例,但许多病毒感染仍然没有有效的治疗方法。这不仅适用于最近蔓延到人类的人畜共患病毒(如严重急性呼吸综合征冠状病毒2型(SARS-CoV-2))引起的传染病暴发,也适用于通过接种疫苗得到控制的古老病毒性疾病,如天花、脊髓灰质炎、麻疹和狂犬病。由流感、呼吸道合胞病毒(RSV)和鼻病毒引起的地方性呼吸道感染是一个基本上未解决的问题,其相关发病率可能会随着空气污染的增加而恶化。此外,气候变化将使工业化国家面临病毒性出血热死灰复燃的危险,这也可能成为全球性传染病。在此,我们总结了最近在寻找新的抗病毒药物方面取得的进展,以对抗世界人口在未来十年中将日益频繁地面对的这些不同威胁。
{"title":"Anno 2021: Which antivirals for the coming decade?","authors":"Elisabetta Groaz,&nbsp;Erik De Clercq,&nbsp;Piet Herdewijn","doi":"10.1016/bs.armc.2021.09.004","DOIUrl":"https://doi.org/10.1016/bs.armc.2021.09.004","url":null,"abstract":"<p><p>Despite considerable progress in the development of antiviral drugs, among which anti-immunodeficiency virus (HIV) and anti-hepatitis C virus (HCV) medications can be considered real success stories, many viral infections remain without an effective treatment. This not only applies to infectious outbreaks caused by zoonotic viruses that have recently spilled over into humans such as severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), but also ancient viral diseases that have been brought under control by vaccination such as variola (smallpox), poliomyelitis, measles, and rabies. A largely unsolved problem are endemic respiratory infections due to influenza, respiratory syncytial virus (RSV), and rhinoviruses, whose associated morbidity will likely worsen with increasing air pollution. Furthermore, climate changes will expose industrialized countries to a dangerous resurgence of viral hemorrhagic fevers, which might also become global infections. Herein, we summarize the recent progress that has been made in the search for new antivirals against these different threats that the world population will need to confront with increasing frequency in the next decade.</p>","PeriodicalId":8033,"journal":{"name":"Annual Reports in Medicinal Chemistry","volume":"57 ","pages":"49-107"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563371/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10363018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Improving properties of the nucleobase analogs T-705/T-1105 as potential antiviral. 提高核碱基类似物T-705/T-1105作为潜在抗病毒药物的性能。
4区 化学 Q3 Chemistry Pub Date : 2021-01-01 DOI: 10.1016/bs.armc.2021.08.002
Xiao Jia, Benedikt Ganter, Chris Meier

In this minireview we describe our work on the improvement of the nucleobase analogs Favipiravir (T-705) und its non-fluorinated derivative T-1105 as influenza and SARS-CoV-2 active compounds. Both nucleobases were converted into nucleotides and then included in our nucleotide prodrugs technologies cycloSal-monophosphates, DiPPro-nucleoside diphosphates and TriPPPro-nucleoside triphosphates. Particularly the DiPPro-derivatives of T-1105-RDP proved to be very active against influenza viruses. T-1105-derivatives in general were found to be more antivirally active as compared to their T-705 counterpart. This may be due to the low chemical stability of all ribosylated derivatives of T-705. The ribosyltriphosphate derivative of T-1105 was studied for the potential to act as a inhibitor of the SARS-CoV-2 RdRp and was found to be an extremely potent compound causing lethal mutagenesis. The pronucleotide technologies, the chemical synthesis, the biophysical properties and the biological effects of the compounds will be addressed as well.

在这篇综述中,我们描述了我们在改进核碱基类似物Favipiravir (T-705)及其无氟衍生物T-1105作为流感和SARS-CoV-2活性化合物方面的工作。这两种核碱基都被转化为核苷酸,然后被纳入我们的核苷酸前药技术,即cyclosal - monophosp磷酸盐、dipppro -nucleoside diphosphate和TriPPPro-nucleoside triphosphate。特别是T-1105-RDP的dippro衍生物被证明对流感病毒具有很强的活性。总的来说,与T-705相比,t -1105衍生物的抗病毒活性更高。这可能是由于T-705的所有核基化衍生物的化学稳定性都很低。研究了T-1105的三磷酸核糖基衍生物作为SARS-CoV-2 RdRp抑制剂的潜力,发现它是一种非常有效的化合物,可引起致命的诱变。对化合物的原核苷酸技术、化学合成、生物物理性质和生物效应进行了综述。
{"title":"Improving properties of the nucleobase analogs T-705/T-1105 as potential antiviral.","authors":"Xiao Jia,&nbsp;Benedikt Ganter,&nbsp;Chris Meier","doi":"10.1016/bs.armc.2021.08.002","DOIUrl":"https://doi.org/10.1016/bs.armc.2021.08.002","url":null,"abstract":"<p><p>In this minireview we describe our work on the improvement of the nucleobase analogs Favipiravir (T-705) und its non-fluorinated derivative T-1105 as influenza and SARS-CoV-2 active compounds. Both nucleobases were converted into nucleotides and then included in our nucleotide prodrugs technologies cycloSal-monophosphates, Di<i>PP</i>ro-nucleoside diphosphates and Tri<i>PPP</i>ro-nucleoside triphosphates. Particularly the Di<i>PP</i>ro-derivatives of T-1105-RDP proved to be very active against influenza viruses. T-1105-derivatives in general were found to be more antivirally active as compared to their T-705 counterpart. This may be due to the low chemical stability of all ribosylated derivatives of T-705. The ribosyltriphosphate derivative of T-1105 was studied for the potential to act as a inhibitor of the SARS-CoV-2 RdRp and was found to be an extremely potent compound causing lethal mutagenesis. The pronucleotide technologies, the chemical synthesis, the biophysical properties and the biological effects of the compounds will be addressed as well.</p>","PeriodicalId":8033,"journal":{"name":"Annual Reports in Medicinal Chemistry","volume":"57 ","pages":"1-47"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10726367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Coronaviruses and other Novel Antiviral Targets 冠状病毒和其他新的抗病毒靶点
4区 化学 Q3 Chemistry Pub Date : 2021-01-01 DOI: 10.1016/s0065-7743(21)x0003-6
{"title":"Coronaviruses and other Novel Antiviral Targets","authors":"","doi":"10.1016/s0065-7743(21)x0003-6","DOIUrl":"https://doi.org/10.1016/s0065-7743(21)x0003-6","url":null,"abstract":"","PeriodicalId":8033,"journal":{"name":"Annual Reports in Medicinal Chemistry","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55791711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uracil derivatives as non-nucleoside inhibitors of viral infections 尿嘧啶衍生物作为病毒感染的非核苷抑制剂
4区 化学 Q3 Chemistry Pub Date : 2021-01-01 DOI: 10.1016/bs.armc.2021.08.001
A. Khandazhinskaya, E. Matyugina, M. Novikov
{"title":"Uracil derivatives as non-nucleoside inhibitors of viral infections","authors":"A. Khandazhinskaya, E. Matyugina, M. Novikov","doi":"10.1016/bs.armc.2021.08.001","DOIUrl":"https://doi.org/10.1016/bs.armc.2021.08.001","url":null,"abstract":"","PeriodicalId":8033,"journal":{"name":"Annual Reports in Medicinal Chemistry","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54061813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Annual Reports in Medicinal Chemistry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1